EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy

Ping-Chih Hsu, John Wen-Cheng Chang, Li-Chung Chiu, Cheng-Ta Yang, Scott Chih-Hsi Kuo, Yueh-Fu Fang, Chiao-En Wu

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03727-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Ping-Chih Hsu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, 33305, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, Chang Gung Memorial Hospital, Linkou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives Genomic alterations after resistance to osimertinib therapy in advanced T790M-mutated non-small cell lung cancer (NSCLC) are complex and poorly understood. In this study, we aimed to detect these genomic alternations via comprehensive next-generation sequencing (NGS) of tissue and liquid biopsies. Patients and methods From September 2020 to June 2021, 31 stage IIIB/IV T790M-mutated NSCLC patients who exhibited progressive disease after osimertinib therapy and provided written informed consent were recruited. Liquid and tissue biopsy samples for NGS testing were collected from 31 and 18 patients, respectively. Eighteen study patients had paired NGS data from tissue and liquid biopsies.

Results

With respect to the T790M mutation status, the preservation and loss rates were 33% and 67%, respectively, in both liquid and tissue biopsy samples. Five patients (16.1%) had the C797S mutation (4 liquid samples and 1 tissue sample). Two (6.5%) had MET mutations, 3 (9.7%) had BRAF-V600E mutations, and 1 (3.2%) had a KRAS-G12C mutation. Among the 18 patients who underwent tissue rebiopsies, those with preserved T790M mutation had significantly longer progression-free survival (PFS) with osimertinib therapy than those with T790M mutation loss (10.8 vs. 5.0 months, P = 0.045). Among all patients, those with T790M mutation loss in liquid biopsy samples had longer PFS after osimertinib therapy (10.8 vs. 7.5 months, P = 0.209) and postprogression survival (17.7 vs. 9.6 months, P = 0.132) than those with preserved T790M mutation based on liquid biopsies.

Conclusions

NGS using either tissue or liquid biopsy samples from advanced T790M-mutated NSCLC patients with acquired resistance to osimertinib therapy can detect various genomic alternations. Future studies focusing on subsequent tailored therapies on the basis of NGS results are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsDrug Resistance, NeoplasmMutationAcrylamidesAniline CompoundsHumansErbB ReceptorsFemaleMiddle AgedMaleAgedHigh-Throughput Nucleotide SequencingAdultAged, 80 and overAntineoplastic AgentsProtein Kinase InhibitorsIndolesPyrimidines

Stichwörter der Autor:innen

Acquired resistanceEpidermal growth factor receptor mutationNon-small cell lung cancer (NSCLC)OsimertinibT790MTyrosine kinase inhibitor

Substanzen

osimertinibErbB ReceptorsEGFR protein, humanAcrylamidesAniline CompoundsAntineoplastic AgentsProtein Kinase InhibitorsIndolesPyrimidines

Autor:innen und Institutionen

  • Division of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, 33305, Taiwan.
  • Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, 33302, Taiwan.
  • Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, 5, Fu-Hsing Street, Kwei-Shan, Taoyuan, 33305, Taiwan.
  • Department of Internal Medicine, Taoyuan Chang Gung Memorial Hospital, Taoyuan, 33378, Taiwan.
  • Department of Respiratory Therapy, College of Medicine, Chang Gung University, Taoyuan, 33302, Taiwan.
  • Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, 33302, Taiwan. jiaoen@gmail.com.

Förderung

  • Ministry of Science and Technology, Taiwan
  • Chang Gung Memorial Hospital, Linkou

Zitieren

APA

Hsu, P. C., Chang, J. W., Chiu, L. C., Yang, C. T., Kuo, S. C., Fang, Y. F., & Wu, C. E. (2024). Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03727-7

Vancouver

Hsu PC, Chang JW, Chiu LC, Yang CT, Kuo SC, Fang YF, et al. Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03727-7

BibTeX
@article{Hsu2024,
  author = {Hsu, Ping-Chih and Chang, John Wen-Cheng and Chiu, Li-Chung and Yang, Cheng-Ta and Kuo, Scott Chih-Hsi and Fang, Yueh-Fu and Wu, Chiao-En},
  title = {Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03727-7}
}
Kostenlos starten →